Published in Cancer Weekly, September 2nd, 2003
The transaction remains subject to various closing conditions, including the approval of stockholders of IDEC Pharmaceuticals and Biogen and other regulatory approvals and filings.
The proposed merger was announced on June 23, 2003. The combined company will be called BIOGEN IDEC, INC.
IDEC is focused on the discovery, development, and commercialization of targeted immunotherapies for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.